var docs;if (!docs) docs =[]; docs["89"]={"8900":"<p><b>Title</b> FentaNYL / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient for evidence of reduced analgesic effects and/or emergence of possible withdrawal signs/symptoms if fentanyl is used together with a moderate CYP3A4 inducer, particularly if the CYP3A4 inducer is initiated in a patient previously stable on fentanyl. Caution is also warranted if a patient who had been maintained on this combination discontinues the moderate CYP3A4 inducer, as fentanyl concentrations and effects would be expected to increase as the effect of the CYP3A4 inducer diminishes.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The fentanyl prescribing information cautions that drugs capable of inducing CYP3A4 may decrease fentanyl concentrations and effects, possibly also increasing the risk for withdrawal signs and symptoms.<sup>1,2</sup> Specific data with such agents are limited, but a study of the CYP3A inducer rifampin found that the fentanyl AUC was an average of 63% lower with concurrent rifampin.<sup>3</sup> Published case reports describe reduced fentanyl effectiveness in patients who were treated with rifampin.<sup>4,5</sup><br><br>The likely mechanism for this potential interaction is enhanced fentanyl metabolism due to induction of CYP3A, leading to reduced fentanyl serum concentrations.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Duragesic</i> (fentanyl) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; April 2014.</p>\n<p>2. <i>Actiq</i> (fentanyl) [prescribing information]. Frazer, PA: Cephalon, Inc.; June 2012.</p>\n<p>3. Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. <i>Anesthesiology</i>. 2004;101(3):729-737. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15329598\">[PubMed 15329598]</a></p>\n<p>4. Takane H, Nosaka A, Wakushima H, Hosokawa K, Ieiri I. Rifampin reduces the analgesic effect of transdermal fentanyl. <i>Ann Pharmacother</i>. 2005;39(12):2139-2140. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16288064\">[PubMed 16288064]</a></p>\n<p>5. Morii H, Chiba M, Konishi H, Endo Y, Yamaji A. Failure of pain control using transdermal fentanyl during rifampicin treatment. <i>J Pain Symptom Manage</i>. 2007;33(1):5-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17196900\">[PubMed 17196900]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8901":"<p><b>Title</b> HYDROcodone / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> In patients taking hydrocodone, monitor for decreased effects and withdrawal symptoms if a CYP3A4 inducer is initiated. Conversely, monitor patients for increased hydrocodone toxicities, including fatal respiratory depression, if any CYP3A4 inducer is discontinued. Consider hydrocodone dose adjustments until stable effects of the CYP3A4 inducer (either addition or removal) are achieved.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The prescribing information for at least one hydrocodone product (Zohydro ER) warns that CYP3A4 inducers may increase the metabolism of hydrocodone and lead to decreased plasma concentrations, since CYP3A4 plays a major role in hydrocodone metabolism.<sup>1</sup> Lack of efficacy, or development of a withdrawal syndrome could occur. The prescribing information also contains a boxed warning detailing that discontinuation of any CYP3A4 inducer in hydrocodone treated patients could result in an increase in hydrocodone plasma concentrations. This may prolong adverse drug effects and potentially lead to fatal respiratory depression. Monitor patients closely who are taking or discontinuing CYP3A4 inducers, and consider hydrocodone dose adjustments until stable drug effects are achieved.<sup>1</sup> Although the magnitude of this interaction is likely to be greater with strong inducers of CYP3A4, caution with moderate and even weak inducers of CYP3A4 may still be warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zohydro ER</i> (hydrocodone bitartrate) [prescribing information]. San Diego, CA: Zogenix Inc; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8902":"<p><b>Title</b> Ibrutinib / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased ibrutinib effects/therapeutic failure if combined with moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 17 healthy volunteers, the strong CYP3A4 inducer rifampin (600 mg daily for 10 days) decreased the ibrutinib (560 mg single dose given on day 8) maximum serum concentration and AUC 92% and 90%, respectively.<sup>1</sup> Additionally, a physiologically based pharmacokinetic modeling study predicted a possible 80% reduction in ibrutinib AUC with the strong CYP3A4 inducer carbamazepine and a possible 60% reduction in ibrutinib AUC with the moderate CYP3A inducer efavirenz.<sup>2</sup> <br><br>Ibrutinib prescribing information states that because strong CYP3A4 inducers can reduce ibrutinib efficacy, concomitant use of ibrutinib and strong CYP3A4 inducers is not recommended.<sup>3</sup> No recommendation is provided for when ibrutinib is combined with moderate CYP3A4 inducers, but reduced exposure to ibrutinib appears likely and monitoring for reduced effectiveness is probably warranted.<br><br>The mechanism of this interaction is likely induction of CYP3A4, an enzyme responsible for ibrutinib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. <i>Pharmacol Res Perspect</i>. 2015;3(4):e00156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171235\">[PubMed 26171235]</a></p>\n<p>2. de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M. Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling. <i>Clin Pharmacol Ther</i>. 2016;100(5):548-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27367453\">[PubMed 27367453]</a></p>\n<p>3. Imbruvica (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; August 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8903":"<p><b>Title</b> Clarithromycin / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternative antimicrobial therapy for patients receiving a CYP3A inducer. Due to the different antimicrobial activities of clarithromycin and its active 14-hydroxy metabolite, drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin, possibly impairing the intended therapeutic effectiveness of clarithromycin.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The average clarithromycin AUC was 44% lower while the average 14-hydroxyclarithromycin AUC was 57% higher with concurrent use of clarithromycin (500 mg every 12 hours) and rifabutin (300 mg/day) in a study of 34 HIV-positive volunteers.<sup>1</sup> The authors of this study also reported a high incidence of gastrointestinal adverse effects with concurrent therapy, leading them to conclude that this combination would have little clinical usefulness. In another pharmacokinetic study conducted in 16 healthy volunteers, coadministration of etravirine (200 mg twice daily) and clarithromycin (500 mg twice daily) resulted in a 39% decrease in clarithromycin AUC and a 21% increase in 14-hydroxyclarithromycin AUC.<sup>2</sup> <br><br>Consistent with these data, the clarithromycin prescribing information cautions that the decrease in clarithromycin concentrations and increase in 14-hydroxyclarithromycin concentrations may alter the antimicrobial effectiveness of clarithromycin when used in such combinations.<sup>3</sup> Particular caution is advised when treating <i>Mycobacterium avium</i>, as 14-hydroxyclarithromycin has reduced activity against this pathogen. As a result, alternative antimicrobial therapy is recommended when possible.<sup>3</sup> <br><br>The likely mechanism for this interaction is induction of the CYP3A enzyme that mediates the 14-hydroxylation of clarithromycin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. <i>Antimicrob Agents Chemother</i>. 1998;42(3):631-639. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9517944\">[PubMed 9517944]</a></p>\n<p>2. Kakuda TN, Woodfall B, De Marez T, et al. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two phase 1 studies. <i>J Antimicrob Chemother</i>. 2014;69(3):728-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24155058\">[PubMed 24155058]</a></p>\n<p>3. <i>Biaxin</i> (clarithromycin) [prescribing information]. North Chicago, IL: Abbott Laboratories; May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8904":"<p><b>Title</b> Ifosfamide / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use of a moderate CYP3A4 inducer may increase metabolism of ifosfamide, potentially increasing or decreasing ifosfamide therapeutic effects as well as increasing the risk of some toxicities (e.g., nephrotoxicity, neurotoxicity). Monitor patients closely for clinical response and toxicity, and adjust dose as needed.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> Exposure to the active 4-hydroxyifosfamide metabolite of ifosfamide was reduced by an average of 11% with the strong CYP3A4 inducer rifampin in a study of 8 volunteers with incurable malignancies who were receiving palliative ifosfamide (3 g/m<sup>2</sup> given by 24-hour continuous infusion) with or without concurrent rifampin (300 mg orally twice/day for 6 days, starting 3 days prior to the ifosfamide).<sup>1</sup> Exposure to the inactive 2- and 3-dechloroethylifosfamide metabolites, which are themselves inactive but potentially contribute to neurotoxicity via production of chloroacetaldehyde, was reduced by an average of 32% and 72%, respectively. Overall clearance of the parent ifosfamide was increased by an average of 102%. These findings are generally consistent with, but of a lower magnitude than those of an in vitro study in human hepatocytes that reported ifosfamide 4-hydroxylation that was 200% to 400% of control values.<sup>2</sup><br><br>The clinical significance of these findings is uncertain, but the slight decrease in 4-hydroxyifosfamide exposure, without any substantially greater decrease in exposure to the 2- and 3-dechloroethyl metabolites suggests this interaction may negatively impact effectiveness without a clear beneficial effect on toxicity risk. Per ifosfamide prescribing information, coadministration of ifosfamide with CYP3A4 inducers, such as rifampin, may increase the rate of metabolism of ifosfamide to its active alkylating metabolites.<sup>3</sup> This could theoretically increase ifosfamide therapeutic effects as well as the likelihood of some toxicities (e.g., nephrotoxicity, neurotoxicity).<sup>1,3</sup><br><br>The mechanism for this apparent interaction is likely rifampin induction of both CYP3A4 and CYP2B6, resulting in enhanced clearance of ifosfamide to both its 4-hydroxy and its 2- and 3-dechloroethyl metabolites.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kerbusch T, Jansen RL, Mathot RA, et al. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. <i>Clin Pharmacol Ther</i>. 2001;70(2):132-141. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11503007\">[PubMed 11503007]</a></p>\n<p>2. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. <i>Cancer Res</i>. 1997;57(10):1946-1954. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9157990\">[PubMed 9157990]</a></p>\n<p>3. <i>Ifex</i> (ifosfamide) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8905":"<p><b>Title</b> PrednisoLONE (Systemic) / Carbimazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Carbimazole may decrease the serum concentration of PrednisoLONE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for evidence of a reduced clinical response to prednisolone in patients who are receiving carbimazole. Increased prednisolone doses may be necessary.</p> \n<p><b>Discussion</b> The average prednisolone clearance was significantly increased, and the prednisolone elimination half-life was significantly decreased, in those treated with carbimazole in a study of patients with Graves ophthalmopathy who had received carbimazole and l-thyroxine for at least 4 months (n=6) as compared to healthy volunteers (n=6).<sup>1</sup> All patients were euthyroid at the time of the study. These findings are similar to those from a separate study involving methimazole, which is the active metabolite of carbimazole, in which prednisolone clearance was higher in those treated with methimazole than in either a control group that had undergone subtotal thyroidectomy or a healthy volunteer control group.<sup>2</sup><br><br>The specific mechanism for this apparent interaction is uncertain, but that the subjects in this study were euthyroid at the time of the study and the inclusion of a thyroidectomy control group suggest that the observed interaction is unlikely solely due to any underlying thyroid disease.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Legler UF. Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves' ophthalmopathy. <i>Horm Metab Res</i>. 1987;19(4):168-170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3583222\">[PubMed 3583222]</a></p>\n<p>2. Legler UF. Impairment of prednisolone disposition in patients with Graves' disease taking methimazole. <i>J Clin Endocrinol Metab</i>. 1988;66(1):221-223. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3335606\">[PubMed 3335606]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8906":"<p><b>Title</b> PrednisoLONE (Systemic) / MethIMAzole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> MethIMAzole may decrease the serum concentration of PrednisoLONE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor closely for evidence of a reduced clinical response to prednisolone in patients who are receiving methimazole. Increased prednisolone doses may be necessary.</p> \n<p><b>Discussion</b> The average prednisolone clearance was significantly increased in those treated with methimazole in a study of patients with severe infiltrative ophthalmopathy who had received methimazole and l-thyroxine for at least 4 months (n=8) as compared to both patients with ophthalmopathy who had undergone subtotal thyroidectomy (and not methimazole treatment) (n=6) and healthy volunteers (n=6).<sup>1</sup> All patients were euthyroid at the time of the study. These findings are similar to those from a separate study involving carbimazole, which is a pro-drug of methimazole, in which prednisolone clearance was higher in those treated with carbimazole (n=6) than in a healthy volunteer control group (n=6).<sup>2</sup><br><br>The specific mechanism for this apparent interaction is uncertain, but that the subjects in this study were euthyroid at the time of the study and the inclusion of a thyroidectomy control group suggest that the observed interaction is unlikely solely due to any underlying thyroid disease.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Legler UF. Impairment of prednisolone disposition in patients with Graves' disease taking methimazole. <i>J Clin Endocrinol Metab</i>. 1988;66(1):221-223. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3335606\">[PubMed 3335606]</a></p>\n<p>2. Legler UF. Enhanced prednisolone elimination: a possible cause for failure of glucocorticoid therapy in Graves' ophthalmopathy. <i>Horm Metab Res</i>. 1987;19(4):168-170. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3583222\">[PubMed 3583222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8907":"<p><b>Title</b> Vancomycin / Piperacillin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Piperacillin may enhance the nephrotoxic effect of Vancomycin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of acute kidney injury if using this combination. Alternatives to piperacillin/tazobactam may be associated with lower risk in patients requiring vancomycin.</p> \n<p><b>Discussion</b> In a multicenter, prospective, observational study of 242 patients receiving vancomycin, the incidence of acute kidney injury was significantly greater in patients who received piperacillin/tazobactam compared with patients who received either cefepime or meropenem (29.8% vs 8.8%; p &lt;0.001).<sup>1</sup> In a single-center retrospective chart review of 125 patients (aged 20 to 89 years) receiving vancomycin therapy with normal baseline renal function, nephrotoxicity (defined as an increase in serum creatinine by 0.5 mg/dL or 50% above baseline) occurred in 17 patients.<sup>2</sup> Thirteen patients in the nephrotoxicity group received concomitant piperacillin/tazobactam treatment compared to 45 patients in the group without nephrotoxicity [76.5% vs. 41.7%, respectively; adjusted OR=5.4 (95% CI: 1.4 to 20.5)]. Acute hypotensive events were also identified as a significantly more common in the patients developing nephrotoxicity [adjusted OR=20 (1.8 to 226)].<br><br>In a retrospective cohort study of 191 vancomycin-treated patients with normal baseline renal function, nephrotoxicity (defined as an increase in serum creatinine 50% above baseline) occurred in 8.1% and 16.3% of patients treated with vancomycin alone compared to vancomycin with piperacillin/tazobactam.<sup>3</sup> The overall incidence of sepsis was higher in the combination group. An increased risk of nephrotoxicity was associated with trough concentrations of 15 mg/L or greater (OR=3.67) in both groups.<br><br>In a retrospective matched-cohort study involving 224 patients with normal renal function, a significantly higher incidence of acute kidney injury (AKI) occurred in patients who received vancomycin with piperacillin-tazobactam compared to patients who received vancomycin with cefepime [34.8% vs. 12.5%; OR=3.7 (1.9 to 7.4)].<sup>4</sup> A matched-pairs analysis revealed similar findings.<br><br>In a case-control study, 24 out of 69 patients who had undergone antibiotic-impregnated cement spacer placement with vancomycin and/or an aminoglycoside developed AKI (defined as an increase in serum creatinine by 0.5 mg/dL or 50% above baseline).<sup>5</sup> Exposure to piperacillin/tazobactam within 7 days after spacer placement was greater in the AKI group compared to the no AKI group [31% vs. 12%; OR=3.6 (1.2 to 11.1)].<br><br>Controlled studies are needed to confirm this interaction and clarify its mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mullins BP, Kramer CJ, Bartel BJ, Catlin JS, Gilder RE. Comparison of the nephrotoxicity of vancomycin in combination with cefepime, meropenem, or piperacillin/tazobactam: a prospective, multicenter study [published online February 1, 2018]. <i>Ann Pharmacother</i>. doi: 10.1177/1060028018757497. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29442542\">[PubMed 29442542]</a></p>\n<p>2. Meaney CJ, Hynicka LM, Tsoukleris MG. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. <i>Pharmacotherapy</i>. 2014;34(7):653-661. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24700598\">[PubMed 24700598]</a></p>\n<p>3. Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. <i>Pharmacotherapy</i>. 2014;34(7):670-676. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24855041\">[PubMed 24855041]</a></p>\n<p>4. Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime. <i>Pharmacotherapy</i>. 2014;34(7):662-669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24753221\">[PubMed 24753221]</a></p>\n<p>5. Reed EE, Johnston J, Severing J, Stevenson KB, Deutscher M. Nephrotoxicity Risk Factors and Intravenous Vancomycin Dosing in the Immediate Postoperative Period Following Antibiotic-Impregnated Cement Spacer Placement. <i>Ann Pharmacother</i>. 2014;48(8):962-969. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24823910\">[PubMed 24823910]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8908":"<p><b>Title</b> Astemizole / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Darunavir may increase the serum concentration of Astemizole. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The concomitant use of darunavir (when combined with either cobicistat or ritonavir) with astemizole should be avoided. The combination is contraindicated in Canadian labeling. US labeling does not describe this combination specifically, but does contraindicate the use of darunavir with CYP3A4 substrates where elevated plasma concentrations are associated with serious and/or life-threatening events (eg, astemizole, terfenadine). Concomitant use is expected to substantially increase the risk for serious cardiac toxicities, including QTc prolongation and/or the development of torsades de pointes.</p> \n<p><b>Discussion</b> Canadian labeling for darunavir and darunavir/cobicistat contraindicates use with astemizole due to the risk for serious and life-threatening reactions such as QTc prolongation and cardiac arrhythmias (torsades de pointes).<sup>1,2</sup> US labeling does not describe this combination specifically, but does contraindicate the use of darunavir with CYP3A4 substrates where elevated plasma concentrations are associated with serious and/or life-threatening events.<sup>3</sup> <br><br>Although there are no specific data on the mechanism of this interaction, it is likely due to the ability of darunavir (when combined with ritonavir or cobicistat) to inhibit CYP3A4, an enzyme partially responsible for astemizole metabolism.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Prezista</i> (darunavir) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; September 2014</p>\n<p>2. <i>Prezcobix</i> (darunavir/cobicistat) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; June 2014.</p>\n<p>3. <i>Prezista</i> (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; April 2014.</p>\n<p>4. Matsumoto S, Yamazoe Y. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine.<i>Br J Clin Pharmacol</i>. 2001;51(2):133-142. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11259984\">[PubMed 11259984]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8909":"<p><b>Title</b> Terfenadine / Darunavir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Darunavir may increase the serum concentration of Terfenadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The concomitant use of darunavir (when combined with either cobicistat or ritonavir) with terfenadine should be avoided. The combination is contraindicated in Canadian labeling. US labeling does not describe this combination specifically, but does contraindicate the use of darunavir with CYP3A4 substrates where elevated plasma concentrations are associated with serious and/or life-threatening events (eg, astemizole, terfenadine). Concomitant use is expected to substantially increase the risk for serious cardiac toxicities, including QTc prolongation and/or the development of torsades de pointes.</p> \n<p><b>Discussion</b> Canadian labeling for darunavir and darunavir/cobicistat contraindicates use with terfenadine due to the risk for serious and life-threatening reactions such as QTc prolongation and cardiac arrhythmias (torsades de pointes).<sup>1,2</sup> US labeling does not describe this combination specifically, but does contraindicate the use of darunavir with CYP3A4 substrates where elevated plasma concentrations are associated with serious and/or life-threatening events.<sup>3</sup> <br><br>Although there are no specific data on the mechanism of this interaction, it is likely due to the ability of darunavir (when combined with ritonavir or cobicistat) to inhibit CYP3A4, an enzyme responsible for terfenadine metabolism.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Prezista</i> (darunavir) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; September 2014</p>\n<p>2. <i>Prezcobix</i> (darunavir/cobicistat) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; June 2014.</p>\n<p>3. <i>Prezista</i> (darunavir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; April 2014.</p>\n<p>4. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. <i>Drug Metab Dispos</i>. 1993;21(3):403-409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8100494\">[PubMed 8100494]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8910":"<p><b>Title</b> Ibrutinib / Flaxseed Oil</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The ibrutinib Canadian product monograph recommends avoiding this combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Flaxseed Oil may enhance the antiplatelet effect of Ibrutinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increased monitoring for evidence of bleeding/bleeding risk (eg, easily bruising, blood in stools or urine, prolonged or uncontrolled bleeding) in patients receiving ibrutinib in combination with flaxseed oil. The ibrutinib Canadian product monograph recommends avoiding this combination.</p> \n<p><b>Discussion</b> The ibrutinib Canadian product monograph states that its use in combination with certain supplements (flaxseed oil, omega-3 fatty acids, and vitamin E) should be avoided due to a theoretical potential for the supplements to increase bleeding risk via antiplatelet effects.<sup>1</sup> Ibrutinib US prescribing information, in contrast, recommends only a careful risk-benefit assessment for use with anticoagulant or antiplatelet agents.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Imbruvica</i> (ibrutinib) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; November 2014.</p>\n<p>2. <i>Imbruvica</i> (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8911":"<p><b>Title</b> Ibrutinib / Omega-3 Fatty Acids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The ibrutinib Canadian product monograph recommends avoiding this combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Omega-3 Fatty Acids may enhance the antiplatelet effect of Ibrutinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increased monitoring for evidence of bleeding/bleeding risk (eg, easily bruising, blood in stools or urine, prolonged or uncontrolled bleeding) in patients receiving ibrutinib in combination with omega-3 fatty acids. The ibrutinib Canadian product monograph recommends avoiding this combination.</p> \n<p><b>Discussion</b> The ibrutinib Canadian product monograph states that its use in combination with certain supplements (flaxseed oil, omega-3 fatty acids, and vitamin E) should be avoided due to a theoretical potential for the supplements to increase bleeding risk via antiplatelet effects.<sup>1</sup> Ibrutinib US prescribing information, in contrast, recommends only a careful risk-benefit assessment for use with anticoagulant or antiplatelet agents.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Imbruvica</i> (ibrutinib) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; November 2014.</p>\n<p>2. <i>Imbruvica</i> (ibrutinib) [prescribing information]. Horsham, PA: Janssen Biotech Inc; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8913":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inducers) / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of the CYP substrates listed in this monograph if a CYP inducer is initiated/dose increased, and for increased effects if a CYP inducer is discontinued/dose decreased (note that the opposite effects are expected for some inactive prodrugs).</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inducers) Interacting Members</b> Abemaciclib, Abiraterone Acetate, Acalabrutinib, Alfuzosin, ALPRAZolam, Amiodarone, AmLODIPine, Apixaban, Apremilast, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Armodafinil, Artemether, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Bedaquiline, Benidipine, Benzhydrocodone, Benzphetamine, Bisoprolol, Blonanserin, Boceprevir, Bortezomib, Bosutinib, Brexpiprazole, Brigatinib, Bromperidol, Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Citalopram, Clarithromycin, ClonazePAM, Clorazepate, Cobicistat, Cobimetinib, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Daclatasvir, Dantrolene, Dapsone (Systemic), Darifenacin, Darunavir, Dasabuvir, Dasatinib, Deflazacort, Delavirdine, Dexamethasone (Systemic), DiazePAM, Dienogest, Digitoxin, DilTIAZem, Disopyramide, DOCEtaxel, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Efavirenz, Elbasvir, Eliglustat, Elvitegravir, Enzalutamide, Eplerenone, Erlotinib, Erythromycin (Systemic), Escitalopram, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Eszopiclone, Ethinyl Estradiol, Ethosuximide, Etizolam, Etoposide, Etoposide Phosphate, Etoricoxib, Etravirine, Everolimus, Exemestane, Felbamate, Felodipine, Fesoterodine, Flibanserin, Flurazepam, Fosamprenavir, Fosaprepitant, Gefitinib, Gemigliptin, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Idelalisib, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ixazomib, Ketoconazole (Systemic), Lacidipine, Lansoprazole, Lapatinib, Lercanidipine, Levonorgestrel (Systemic), Lidocaine (Systemic), Linagliptin, Lomitapide, Losartan, Lovastatin, Lumefantrine, Lurasidone, Lynestrenol, Macimorelin, Macitentan, Manidipine, Maraviroc, MedroxyPROGESTERone, Mefloquine, Mestranol, Methadone, Mianserin, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Modafinil, Naldemedine, Naloxegol, Nefazodone, Nelfinavir, Neratinib, Netupitant, Nevirapine, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Norethindrone, Norgestrel, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Ondansetron, Osimertinib, Ospemifene, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Perampanel, Pimozide, Piperaquine, Pipotiazine, Praziquantel, Primaquine, Progesterone, QUEtiapine, QuiNIDine, QuiNINE, RABEprazole, Radotinib, Ranolazine, Regorafenib, Repaglinide, Ribociclib, Rifabutin, Rilpivirine, Riociguat, Ritonavir, Rivaroxaban, Roflumilast, Rolapitant, RomiDEPsin, Saquinavir, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tamoxifen, Tamsulosin, Tasimelteon, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tetracycline (Systemic), Tezacaftor, TiaGABine, Tibolone, Ticagrelor, Ticlopidine, Tipranavir, Tofacitinib, Tolterodine, Tolvaptan, Toremifene, Trabectedin, TraMADol, TraZODone, Triazolam, Trimethoprim, Trimipramine, Ulipristal, Valbenazine, Vandetanib, Velpatasvir, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, Vilazodone, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vortioxetine, Voxilaprevir, Zolpidem, Zonisamide, Zopiclone</p>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> The CYP inducers listed in this monograph will probably increase the metabolism of the substrates of this pathway. Substrate clearance would increase and serum concentrations would decrease. Decreased effects of the substrates are expected (note that the opposite effect is expected for some inactive prodrugs).<br><br>CYP substrates are included in this monograph because a) the identified cytochrome P450 pathway is responsible for at least 30% of the metabolism of the substrate; and b) a significant decrease in serum concentration of the substrate (ie, more than 50%) could result in clinically relevant pharmacodynamic effects.<br><br>CYP inducers have been labeled “moderate” because they have been shown to cause significant increases in CYP activity, and, as a result, significant increases in the clearance of drugs metabolized by this pathway.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bjornsson TD, Callaghan JT, Einolf HJ, et al; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. <i>J Clin Pharmacol</i>. 2003;43(5):443-469. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12751267\">[PubMed 12751267]</a></p>\n<p>2. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry: Drug Interaction Studies -- Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf. Published February 2012. Accessed March 18, 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8914":"<p><b>Title</b> Imidafenacin / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Imidafenacin. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased imidafenacin toxicity and anticholinergic effects (eg, dry mouth, dry eyes, blurred vision, urinary retention, constipation) if combined with a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In pharmacokinetic study conducted in 10 healthy volunteers, coadministration of itraconazole (200 mg daily for 9 days) with imidafenacin (0.1 mg single dose) resulted in a 1.3-fold increase in the maximum serum concentration and a 1.8-fold increase in the AUC of imidafenacin.<sup>1,2</sup><br><br>Although not completely investigated, the likely mechanism of this potential interaction is itraconazole-mediated inhibition of CYP3A4, an enzyme at least partially responsible for imidafenacin metabolism.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ohno T, Nakayama K, Nakade S, et al. Effect of itraconazole on the pharmacokinetics of imidafenacin in healthy subjects. <i>J Clin Pharmacol</i>. 2008;48(3):330-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18218784\">[PubMed 18218784]</a></p>\n<p>2. <i>Uritos</i> (imidafenacin) [summary of product characteristics]. Chiyoda-ku, Tokyo, Japan: Kyorin Pharmaceutical Co Ltd; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8915":"<p><b>Title</b> Agents with Antiplatelet Properties / Limaprost</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Limaprost may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination closely for evidence of bleeding, particularly those patients who may have other risk factors for bleeding.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The limaprost labeling cautions that concurrent use with antiplatelet, anticoagulant, or thrombolytic agents may result in an increased risk for bleeding.<sup>1</sup> Close monitoring is recommended.<br><br>A published case report describes a 66-year-old patient who experienced significant epistaxis during concurrent therapy with limaprost and paroxetine,<sup>2</sup> which has been associated with antiplatelet actions due to its inhibition of serotonin uptake. The patient was receiving limaprost 15 mcg/day and paroxetine 50 mg/day at the time of the epistaxis. The doses of both drugs were decreased to limaprost 10 mcg/day and paroxetine 40 mg/day, with a later increase in limaprost back to 15 mcg/day with no return of epistaxis. An episode of subconjunctival bleeding in the right eye was noted later but did not result in any immediate dose reduction.<br><br>Limaprost appears capable of inhibiting platelet aggregation,<sup>1</sup> which appears to be the likely mechanism for this potential interaction with other drugs that can increase the bleeding risk.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Opalmon</i> (limaprost alfadex) [Japan Pharmaceutical Reference]. Osaka, Japan: Ono Pharmaceutical Co., Ltd.; July 2010.</p>\n<p>2. Sugiyama N, Sasayama D, Amano N. Massive epistaxis and subconjunctival hemorrhage due to combination of paroxetine and limaprost alfadex: a case report. <i>Prim Care Companion J Clin Psychiatry</i>. 2007;9(3):240-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17632667\">[PubMed 17632667]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8916":"<p><b>Title</b> Anticoagulants / Limaprost</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Limaprost may enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination closely for evidence of bleeding, particularly those patients who may have other risk factors for bleeding.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> The limaprost labeling cautions that concurrent use with antiplatelet, anticoagulant, or thrombolytic agents may result in an increased risk for bleeding.<sup>1</sup> Close monitoring is recommended.<br><br>A published case report describes a 66-year-old patient who experienced significant epistaxis during concurrent therapy with limaprost and paroxetine,<sup>2</sup> which has been associated with antiplatelet actions due to its inhibition of serotonin uptake. The patient was receiving limaprost 15 mcg/day and paroxetine 50 mg/day at the time of the epistaxis. The doses of both drugs were decreased to limaprost 10 mcg/day and paroxetine 40 mg/day, with a later increase in limaprost back to 15 mcg/day with no return of epistaxis. An episode of subconjunctival bleeding in the right eye was noted later but did not result in any immediate dose reduction.<br><br>Limaprost appears capable of inhibiting platelet aggregation,<sup>1</sup> which appears to be the likely mechanism for this potential interaction with other drugs that can increase the bleeding risk.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Opalmon</i> (limaprost alfadex) [Japan Pharmaceutical Reference]. Osaka, Japan: Ono Pharmaceutical Co., Ltd.; July 2010.</p>\n<p>2. Sugiyama N, Sasayama D, Amano N. Massive epistaxis and subconjunctival hemorrhage due to combination of paroxetine and limaprost alfadex: a case report. <i>Prim Care Companion J Clin Psychiatry</i>. 2007;9(3):240-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17632667\">[PubMed 17632667]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8917":"<p><b>Title</b> Thrombolytic Agents / Limaprost</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Limaprost may enhance the adverse/toxic effect of Thrombolytic Agents. The risk for bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving this combination closely for evidence of bleeding, particularly those patients who may have other risk factors for bleeding.</p>\n<div>\n <p><b>Thrombolytic Agents Interacting Members</b> Alteplase, Defibrotide, Reteplase, Streptokinase, Tenecteplase, Urokinase</p>\n</div> \n<p><b>Discussion</b> The limaprost labeling cautions that concurrent use with antiplatelet, anticoagulant, or thrombolytic agents may result in an increased risk for bleeding.<sup>1</sup> Close monitoring is recommended.<br><br>A published case report describes a 66-year-old patient who experienced significant epistaxis during concurrent therapy with limaprost and paroxetine,<sup>2</sup> which has been associated with antiplatelet actions due to its inhibition of serotonin uptake. The patient was receiving limaprost 15 mcg/day and paroxetine 50 mg/day at the time of the epistaxis. The doses of both drugs were decreased to limaprost 10 mcg/day and paroxetine 40 mg/day, with a later increase in limaprost back to 15 mcg/day with no return of epistaxis. An episode of subconjunctival bleeding in the right eye was noted later but did not result in any immediate dose reduction.<br><br>Limaprost appears capable of inhibiting platelet aggregation,<sup>1</sup> which appears to be the likely mechanism for this potential interaction with other drugs that can increase the bleeding risk.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Opalmon</i> (limaprost alfadex) [Japan Pharmaceutical Reference]. Osaka, Japan: Ono Pharmaceutical Co., Ltd.; July 2010.</p>\n<p>2. Sugiyama N, Sasayama D, Amano N. Massive epistaxis and subconjunctival hemorrhage due to combination of paroxetine and limaprost alfadex: a case report. <i>Prim Care Companion J Clin Psychiatry</i>. 2007;9(3):240-241. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17632667\">[PubMed 17632667]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8919":"<p><b>Title</b> Nicorandil / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the hypotensive effect of Nicorandil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient closely for evidence of excessive blood pressure lowering if using nicorandil together with another drug that can lower blood pressure, such as alcohol. Advise patients about the increased potential for dizziness and an impaired ability to drive or operate machinery.</p> \n<p><b>Discussion</b> The nicorandil labeling cautions that nicorandil can lower blood pressure and that concurrent use with alcohol or other blood pressure-reducing medications may result in an excessive blood pressure reduction.<sup>1,2</sup> This particular combination may further increase the potential for related effects such as dizziness or an impaired ability to drive or operate machinery. As described in nicorandil labeling, a study in hypertensive patients showed that single doses of nicorandil (10 mg, 20 mg, and 30 mg) resulted in substantial reductions of both systolic and diastolic blood pressure, with maximal effects at 4 to 6 hours.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ikorel</i> (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.</p>\n<p>2. <i>Ikorel</i> (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8920":"<p><b>Title</b> Nicorandil / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants may enhance the hypotensive effect of Nicorandil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patient closely for evidence of excessive blood pressure lowering if using nicorandil together with another drug that can lower blood pressure, such as a tricyclic antidepressant.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> The nicorandil labeling cautions that nicorandil can lower blood pressure and that concurrent use with tricyclic antidepressants or other blood pressure-reducing medications may result in an excessive blood pressure reduction.<sup>1,2</sup> As described in nicorandil labeling, a study in hypertensive patients showed that single doses of nicorandil (10 mg, 20 mg, and 30 mg) resulted in substantial reductions of both systolic and diastolic blood pressure, with maximal effects at 4 to 6 hours.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ikorel</i> (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.</p>\n<p>2. <i>Ikorel</i> (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8921":"<p><b>Title</b> Nicorandil / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may enhance the adverse/toxic effect of Nicorandil. Gastrointestinal perforation has been reported in association with this combination. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for evidence of gastrointestinal damage with use of this combination, particularly in patients who may be at increased risk for gastrointestinal ulceration.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Nicorandil labeling cautions that gastrointestinal perforations have been reported in association with the concurrent use of nicorandil with corticosteroids.<sup>1,2</sup> <br><br>The specific mechanism for this potential interaction is unknown. Nicorandil and corticosteroid have each been associated with gastrointestinal ulcerations, suggesting that additive or synergistic gastrointestinal damage could be responsible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ikorel</i> (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.</p>\n<p>2. <i>Ikorel</i> (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8922":"<p><b>Title</b> Fluconazole / Amitriptyline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amitriptyline may enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased amitriptyline effects and toxicities (eg, drowsiness, lethargy, unresponsiveness) if combined with fluconazole. Additionally, monitor for increased cardiovascular toxicities, including QTc interval prolongation and torsades de pointes.</p> \n<p><b>Discussion</b> Numerous case reports describe a potential interaction between fluconazole and amitriptyline.<sup>1,2,3,4,5</sup> The reports describe increases in amitriptyline serum levels,<sup>1,2</sup> adverse events (eg, drowsiness, lethargy, unresponsiveness, syncope),<sup>1,2,3,4</sup> and QTc interval prolongation with torsades de pointes<sup>4</sup> when these agents were combined. One report also describes the development of serotonin syndrome after the administration of amitriptyline to a patient taking fluconazole.<sup>5</sup> However, the patient was also taking other serotonergic drugs (ie, meperidine, venlafaxine) making the role of this potential drug interaction in the development of serotonin syndrome unclear.<br><br>Although not fully investigated, the mechanism of this potential interaction is likely due to fluconazole mediated inhibition of numerous cytochrome P450 isoenzymes involved in amitriptyline metabolism. Inhibition of CYP2C19 is likely a major contributor, with inhibition of CYP3A4 and CYP2C9 also playing a role.<sup>6,7</sup> In addition to this potential pharmacokinetic interaction, both fluconazole and amitriptyline have been shown to prolong the QTc interval and their combined use may lead to additive QTc prolongation and risk of serious cardiac toxicities (eg, torsades de pointes).<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Duggal HS. Delirium associated with amitriptyline/fluconazole drug. <i>Gen Hosp Psychiatry</i>. 2003;25(4):297-298. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12850665\">[PubMed 12850665]</a></p>\n<p>2. Newberry DL, Bass SN, Mbanefo CO. A fluconazole/amitriptyline drug interaction in three male adults. <i>Clin Infect Dis</i>. 1997;24(2):270-271. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9114163\">[PubMed 9114163]</a></p>\n<p>3. Robinson RF, Nahata MC, Olshefski RS. Syncope associated with concurrent amitriptyline and fluconazole therapy. <i>Ann Pharmacother</i>. 2000;34(12):1406-1409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11144697\">[PubMed 11144697]</a></p>\n<p>4. Dorsey ST, Biblo LA. Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. <i>Am J Emerg Med</i>. 2000;18(2):227-229. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10750939\">[PubMed 10750939]</a></p>\n<p>5. Dougherty JA, Young H, Shafi T. Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine. <i>Ann Pharmacother</i>. 2002;36(10):1647-1648. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12243617\">[PubMed 12243617]</a></p>\n<p>6. Olesen OV, Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. <i>Pharmacology</i>. 1997;55(5):235-243. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9399333\">[PubMed 9399333]</a></p>\n<p>7. <i>Diflucan</i> (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2013.</p>\n<p>8. Amitriptyline [prescribing information]. Huntsville, AL: Qualitest Pharmaceuticals; May 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8923":"<p><b>Title</b> Nisoldipine / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of nisoldipine with moderate CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> A comparison of nisoldipine pharmacokinetic variables in patients with epilepsy receiving phenytoin (n=12) to age- and gender-matched healthy controls (n=12) found that nisoldipine AUC was approximately 90% lower in epileptic patients concurrently receiving phenytoin (1.6 vs 15.2 h*mcg/L).<sup>1</sup> Similarly, nisoldipine US prescribing information states that the combination of phenytoin and nisoldipine resulted in a reduction of nisoldipine concentrations to undetectable levels.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is phenytoin induction of CYP3A4-mediated nisoldipine metabolism. Nisoldipine prescribing information recommends avoiding CYP3A4 inducers in patients treated with nisoldipine.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Michelucci R, Cipolla G, Passarelli D, et al. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. <i>Epilepsia</i>. 1996;37(11):1107-1110. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8917062\">[PubMed 8917062]</a></p>\n<p>2. <i>Sular</i> (nisoldipine) [prescribing information]. Florham Park, NJ: Shionogi Inc; March 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8924":"<p><b>Title</b> Simeprevir / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of simeprevir with any moderate inducer of CYP3A4 is not recommended.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> According to simeprevir US prescribing information, the simeprevir minimum serum concentration was an average of 91% lower with concurrent use of the moderate CYP3A4 inducer efavirenz in a study of subjects who received simeprevir (150 mg daily) with efavirenz (600 mg daily) for 14 days.<sup>1</sup> The simeprevir AUC was an average of 71% lower with efavirenz.<br><br>The suspected mechanism for this interaction is induction of the CYP3A4 enzyme primarily responsible for simeprevir metabolism, resulting in reduced simeprevir concentrations.<br><br>Based on expectations that all moderate or strong CYP3A4 inducers may similarly reduce simeprevir concentrations, possibly interfering with its clinical effectiveness, the simeprevir prescribing information states that concurrent use of simeprevir with moderate or strong CYP3A4 inducers is not recommended.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Olysio</i> (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8925":"<p><b>Title</b> Methadone / Cobicistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: No increased monitoring appears necessary if the cobicistat regimen also contains elvitegravir. Increased monitoring for opioid effects is warranted if methadone is combined with cobicistat regimens that do not contain elvitegravir.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Methadone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased methadone effects and toxicity if combined with cobicistat. No increased monitoring appears necessary if the cobicistat regimen also contains elvitegravir.</p> \n<p><b>Discussion</b> Methadone US prescribing information warns that because the CYP3A4 isoenzyme plays a major role in the metabolism of methadone, drugs that inhibit CYP3A4 activity (eg, cobicistat) may cause decreased clearance of methadone and lead to increased or prolonged opioid effects.<sup>1</sup> US prescribing information for some cobicistat-containing products also states that the combination of cobicistat and methadone may result in increased methadone exposure and recommends careful monitoring of opioid effects.<sup>2,3,4</sup><br><br>In the only clinical study evaluating the potential interaction between these two agents, the administration of elvitegravir/cobicistat (150 mg/150 mg daily for 10 days) to 11 HIV-negative patients stabilized on methadone therapy (80 mg to 120 mg daily) resulted in no change to the AUC or maximum serum concentration of methadone.<sup>5</sup> <br><br>Although no interaction was reported in this study, elvitegravir may have affected the results. Methadone is metabolized by numerous CYP isoenzymes, including CYP2C9.<sup>1</sup> Because elvitegravir is a moderate inducer of CYP2C9<sup>6</sup> the induction effects of elvitegravir may have offset the inhibition effects of cobicistat. The effect of cobicistat alone (or in combination with drugs without the potential to affect methadone metabolism) on methadone pharmacokinetics is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Dolophine</i> (methadone) [prescribing information]. Columbus, OH: Roxane Laboratories Inc; April 2014.</p>\n<p>2. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; September 2014.</p>\n<p>3. <i>Evotaz</i> (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2015.</p>\n<p>4. <i>Prezcobix</i> (darunavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 201</p>\n<p>5. Bruce RD, Winkle P, Custodio JM, et al. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. <i>Antimicrob Agents Chemother</i>. 2013;57(12):6154-6157. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24080665\">[PubMed 24080665]</a></p>\n<p>6. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, tenofovir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; August 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8926":"<p><b>Title</b> Riociguat / Apremilast</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Apremilast may enhance the hypotensive effect of Riociguat. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of riociguat with nonselective phosphodiesterase inhibitors or phosphodiesterase type 5 inhibitors is contraindicated due to the risk of hypotension. While other phosphodiesterase inhibitors, such as apremilast, are not specifically contraindicated with riociguat, concomitant use should be undertaken with caution and patients should be monitored for the development of hypotension.</p> \n<p><b>Discussion</b> According to the riociguat prescribing information, use of single doses of riociguat (0.5 mg and 1 mg, sequential) in 7 patients with pulmonary arterial hypertension who were stable on the phosphodiesterase 5 (PDE5) inhibitor sildenafil (20 mg 3 times/day) was associated with additive hemodynamic effects.<sup>1</sup> Additionally, it is noted that among patients who received riociguat 1 to 2.5 mg 3 times/day together with sildenafil (20 mg 3 times/day) one death occurred that was deemed possibly related to the combination of riociguat and sildenafil.<sup>1</sup> A greater rate of drug discontinuation was also observed in patients receiving this combination. No clinical studies have been conducted with riociguat and other types of phosphodiesterase inhibitors so the combined effect on blood pressure is unknown.<br><br>Riociguat works by stimulating soluble guanylate cyclase, which is the receptor for nitric oxide, enhancing the production of cGMP. Similarly, phosphodiesterase inhibitors inhibit the breakdown of cyclic nucleotides that result in vasodilation such as cGMP or cAMP, resulting in possible additive or synergistic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Adempas</i> (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8927":"<p><b>Title</b> Riociguat / Ibudilast</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ibudilast may enhance the hypotensive effect of Riociguat. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of riociguat with nonselective phosphodiesterase inhibitors, such as ibudilast, is contraindicated due to the risk of hypotension.</p> \n<p><b>Discussion</b> According to the riociguat prescribing information, use of single doses of riociguat (0.5 mg and 1 mg, sequential) in 7 patients with PAH who were stable on the phosphodiesterase 5 (PDE5) inhibitor sildenafil (20 mg 3 times/day) was associated with additive hemodynamic effects.<sup>1</sup> Additionally, it is noted that among patients who received riociguat 1 mg-2.5 mg three times/day together with sildenafil (20 mg 3 times/day) one death occurred that was deemed possibly related to the combination of riociguat and sildenafil.<sup>1</sup> A greater rate of drug discontinuation was also observed in patients receiving this combination.<br><br>Riociguat works by stimulating soluble guanylate cyclase, which is the receptor for nitric oxide, enhancing the production of cGMP. Similarly, phosphodiesterase inhibitors inhibit the breakdown of cGMP, resulting in additive or synergistic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Adempas</i> (riociguat) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; October 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8928":"<p><b>Title</b> Potassium-Sparing Diuretics / Nicorandil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nicorandil may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations and for any other evidence of hyperkalemia.</p>\n<div>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone, Triamterene</p>\n</div> \n<p><b>Discussion</b> Published reports describe patients who have experienced episodes of hyperkalemia attributed, at least in part, to nicorandil.<sup>1,2</sup> The labeling for at least one nicorandil product warns that concurrent use with drugs that can increase serum potassium could increase the risk for hyperkalemia and should be undertaken with caution,<sup>3</sup> but the labeling for some nicorandil products does not include this warning.<sup>4,5</sup><br><br>The mechanism for this potential interaction appears to be a result of the mechanism by which nicorandil, an agent that opens ATP-dependent potassium (K-ATP) channels, works. Nicorandil-induced opening of the K-ATP channels leads to an efflux of potassium from intracellular spaces, leading to an increase in serum potassium. Concurrent use of other agents that increase serum potassium would increase the risk of hyperkalemia due to additive effects of both agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee HH, Hsu PC, Lin TH, Lai WT, Sheu SH. Nicorandil-induced hyperkalemia in a uremic patient. <i>Case Rep Med</i>. 2012;2012:812178. doi: 10.1155/2012/812178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23118767\">[PubMed 23118767]</a></p>\n<p>2. Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. <i>Lancet</i>. 2005;365(9474):1873-1875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15924984\">[PubMed 15924984]</a></p>\n<p>3. <i>Ikorel</i> (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2014.</p>\n<p>4. <i>Ikorel</i> (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.</p>\n<p>5. <i>Sigmart</i> (nicorandil) [Japan Pharmaceutical Reference]. Tokyo, Japan: Chugai Pharmaceutical Co., Ltd.; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8929":"<p><b>Title</b> Angiotensin II Receptor Blockers / Nicorandil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nicorandil may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations and for any other evidence of hyperkalemia.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n</div> \n<p><b>Discussion</b> Published reports describe patients who have experienced episodes of hyperkalemia attributed, at least in part, to nicorandil.<sup>1,2</sup> The labeling for at least one nicorandil product warns that concurrent use with drugs that can increase serum potassium could increase the risk for hyperkalemia and should be undertaken with caution,<sup>3</sup> but the labeling for some nicorandil products does not include this warning.<sup>4,5</sup><br><br>The mechanism for this potential interaction appears to be a result of the mechanism by which nicorandil, an agent that opens ATP-dependent potassium (K-ATP) channels, works. Nicorandil-induced opening of the K-ATP channels leads to an efflux of potassium from intracellular spaces, leading to an increase in serum potassium. Concurrent use of other agents that increase serum potassium would increase the risk of hyperkalemia due to additive effects of both agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee HH, Hsu PC, Lin TH, Lai WT, Sheu SH. Nicorandil-induced hyperkalemia in a uremic patient. <i>Case Rep Med</i>. 2012;2012:812178. doi: 10.1155/2012/812178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23118767\">[PubMed 23118767]</a></p>\n<p>2. Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. <i>Lancet</i>. 2005;365(9474):1873-1875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15924984\">[PubMed 15924984]</a></p>\n<p>3. <i>Ikorel</i> (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2014.</p>\n<p>4. <i>Ikorel</i> (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.</p>\n<p>5. <i>Sigmart</i> (nicorandil) [Japan Pharmaceutical Reference]. Tokyo, Japan: Chugai Pharmaceutical Co., Ltd.; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8930":"<p><b>Title</b> Angiotensin-Converting Enzyme Inhibitors / Nicorandil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nicorandil may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations and for any other evidence of hyperkalemia.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n</div> \n<p><b>Discussion</b> Published reports describe patients who have experienced episodes of hyperkalemia attributed, at least in part, to nicorandil.<sup>1,2</sup> The labeling for at least one nicorandil product warns that concurrent use with drugs that can increase serum potassium could increase the risk for hyperkalemia and should be undertaken with caution,<sup>3</sup> but the labeling for some nicorandil products does not include this warning.<sup>4,5</sup><br><br>The mechanism for this potential interaction appears to be a result of the mechanism by which nicorandil, an agent that opens ATP-dependent potassium (K-ATP) channels, works. Nicorandil-induced opening of the K-ATP channels leads to an efflux of potassium from intracellular spaces, leading to an increase in serum potassium. Concurrent use of other agents that increase serum potassium would increase the risk of hyperkalemia due to additive effects of both agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee HH, Hsu PC, Lin TH, Lai WT, Sheu SH. Nicorandil-induced hyperkalemia in a uremic patient. <i>Case Rep Med</i>. 2012;2012:812178. doi: 10.1155/2012/812178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23118767\">[PubMed 23118767]</a></p>\n<p>2. Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. <i>Lancet</i>. 2005;365(9474):1873-1875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15924984\">[PubMed 15924984]</a></p>\n<p>3. <i>Ikorel</i> (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2014.</p>\n<p>4. <i>Ikorel</i> (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.</p>\n<p>5. <i>Sigmart</i> (nicorandil) [Japan Pharmaceutical Reference]. Tokyo, Japan: Chugai Pharmaceutical Co., Ltd.; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8931":"<p><b>Title</b> Aliskiren / Nicorandil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nicorandil may enhance the hyperkalemic effect of Aliskiren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations and for any other evidence of hyperkalemia.</p> \n<p><b>Discussion</b> Published reports describe patients who have experienced episodes of hyperkalemia attributed, at least in part, to nicorandil.<sup>1,2</sup> The labeling for at least one nicorandil product warns that concurrent use with drugs that can increase serum potassium could increase the risk for hyperkalemia and should be undertaken with caution,<sup>3</sup> but the labeling for some nicorandil products does not include this warning.<sup>4,5</sup><br><br>The mechanism for this potential interaction appears to be a result of the mechanism by which nicorandil, an agent that opens ATP-dependent potassium (K-ATP) channels, works. Nicorandil-induced opening of the K-ATP channels leads to an efflux of potassium from intracellular spaces, leading to an increase in serum potassium. Concurrent use of other agents that increase serum potassium would increase the risk of hyperkalemia due to additive effects of both agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee HH, Hsu PC, Lin TH, Lai WT, Sheu SH. Nicorandil-induced hyperkalemia in a uremic patient. <i>Case Rep Med</i>. 2012;2012:812178. doi: 10.1155/2012/812178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23118767\">[PubMed 23118767]</a></p>\n<p>2. Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. <i>Lancet</i>. 2005;365(9474):1873-1875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15924984\">[PubMed 15924984]</a></p>\n<p>3. <i>Ikorel</i> (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2014.</p>\n<p>4. <i>Ikorel</i> (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.</p>\n<p>5. <i>Sigmart</i> (nicorandil) [Japan Pharmaceutical Reference]. Tokyo, Japan: Chugai Pharmaceutical Co., Ltd.; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8932":"<p><b>Title</b> Potassium Salts / Nicorandil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Nicorandil may enhance the hyperkalemic effect of Potassium Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations and for any other evidence of hyperkalemia.</p>\n<div>\n <p><b>Potassium Salts Interacting Members</b> Potassium Acetate, Potassium Chloride, Potassium Citrate, Potassium Gluconate, Potassium Iodate, Potassium Iodide, Potassium Phosphate</p>\n</div> \n<p><b>Discussion</b> Published reports describe patients who have experienced episodes of hyperkalemia attributed, at least in part, to nicorandil.<sup>1,2</sup> The labeling for at least one nicorandil product warns that concurrent use with drugs that can increase serum potassium could increase the risk for hyperkalemia and should be undertaken with caution,<sup>3</sup> but the labeling for some nicorandil products does not include this warning.<sup>4,5</sup><br><br>The mechanism for this potential interaction appears to be a result of the mechanism by which nicorandil, an agent that opens ATP-dependent potassium (K-ATP) channels, works. Nicorandil-induced opening of the K-ATP channels leads to an efflux of potassium from intracellular spaces, leading to an increase in serum potassium. Concurrent use of other agents that increase serum potassium would increase the risk of hyperkalemia due to additive effects of both agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lee HH, Hsu PC, Lin TH, Lai WT, Sheu SH. Nicorandil-induced hyperkalemia in a uremic patient. <i>Case Rep Med</i>. 2012;2012:812178. doi: 10.1155/2012/812178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23118767\">[PubMed 23118767]</a></p>\n<p>2. Singer M, Coluzzi F, O'Brien A, Clapp LH. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. <i>Lancet</i>. 2005;365(9474):1873-1875. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15924984\">[PubMed 15924984]</a></p>\n<p>3. <i>Ikorel</i> (nicorandil) [product information]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; July 2014.</p>\n<p>4. <i>Ikorel</i> (nicorandil) [summary of product characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; September 2013.</p>\n<p>5. <i>Sigmart</i> (nicorandil) [Japan Pharmaceutical Reference]. Tokyo, Japan: Chugai Pharmaceutical Co., Ltd.; July 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8933":"<p><b>Title</b> Alcohol (Ethyl) / Cefminox</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Cefminox may enhance the adverse/toxic effect of Alcohol (Ethyl). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of alcohol should be avoided during treatment with cefminox and for at least one week after completion of cefminox treatment. Note that alcohol may be contained in beverages and pharmaceutical products (eg, elixirs).</p> \n<p><b>Discussion</b> The cefminox labeling cautions that the use of alcohol should be avoided during treatment with cefminox and for at least one week after cefminox treatment is completed.<sup>1</sup> Use of alcohol with cefminox may result in a disulfiram-like reaction (i.e., flushing, palpitations, dizziness, nausea, etc.).<sup>1</sup> Studies in rats found evidence that cefminox, along with other cephalosporins with similar chemical structures, increased blood acetaldehyde concentrations.<sup>2</sup> Flushing occurred in 5 of 8 healthy subjects after receiving ethanol (0.5 g/kg) following the administration of 3 doses of cefotetan (2 g every 12 hours), a cephalosporin containing a chemical structure similar to that of cefminox.<sup>3</sup> Other signs and symptoms of disulfiram-like reactions were noted (eg, changes in heart rate and blood pressure); however, no changes in the pharmacokinetics of alcohol or acetaldehyde were observed.<br><br>The mechanism of this potential interaction is uncertain, but it has been proposed that cefminox may inhibit adehyde dehydrogenase, impairing the metabolism of acetaldehyde generated in the metabolism of alcohol.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Meicelin (cefminox) [Japan Pharmaceutical Reference]. Tokyo, Japan: Meiji Seika Kaisha, Ltd.; June 2005.</p>\n<p>2. Kamei C, Sugimoto Y, Muroi N, Tasaka K. Effects of various cephem antibiotics on ethanol metabolism and their structure-activity relations. <i>J Pharm Pharmacol</i>. 1986;38(11):823-828. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2879012\">[PubMed 2879012]</a></p>\n<p>3. Kline SS, Mauro VF, Forney RB Jr, Freimer EH, Somani P. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. <i>Antimicrob Agents Chemother</i>. 1987;31(9):1328-1331. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3479045\">[PubMed 3479045]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8964":"<p><b>Title</b> Memantine / NMDA Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> NMDA Receptor Antagonists may enhance the adverse/toxic effect of Memantine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased memantine adverse effects if combined with another NMDA receptor antagonist.</p>\n<div>\n <p><b>NMDA Receptor Antagonists Interacting Members</b> Amantadine, Dextromethorphan, Ifenprodil, Ketamine, Memantine</p>\n</div> \n<p><b>Discussion</b> According to the memantine prescribing information, the use of memantine with another N-methyl-D-aspartate (NMDA) receptor antagonist has not been systematically evaluated and combined use should be approached with caution.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Namenda</i> (memantine) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals Inc; October 2013.</p>\n<p>2. <i>Namzaric</i> (memantine/donepezil) [prescribing information]. Clonshaug, Dublin, Ireland: Forest Pharmaceuticals Inc; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8965":"<p><b>Title</b> Memantine / Alkalinizing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alkalinizing Agents may increase the serum concentration of Memantine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased effects/toxicity of memantine if coadministered with alkalinizing agents that increase urinary pH.</p>\n<div>\n <p><b>Alkalinizing Agents Interacting Members</b> Potassium Citrate, Sodium Bicarbonate, Sodium Citrate, Sodium Lactate, Tromethamine</p>\n</div> \n<p><b>Discussion</b> In a study of 12 healthy volunteers, the median memantine (10 mg daily) clearance decreased approximately 80% and the median memantine AUC increased approximately 19% when combined with sodium bicarbonate (to achieve a urinary pH of 8) compared with the combination of memantine and ammonium chloride (to achieve a urinary pH of 5).<sup>1</sup> The manufacturer reports that memantine clearance was reduced by approximately 80% when the urinary pH was raised to 8.<sup>2,3</sup> <br><br>Coadministration of memantine with drugs that can increase urinary pH (ie, alkalinizing agents) may result in elevated serum concentrations of memantine and increased risk of adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Freudenthaler S, Meineke I, Schreeb KH, Boakye E, Gundert-Remy U, Gleiter CH. Influence of urine pH and urinary flow on the renal excretion of memantine. <i>Br J Clin Pharmacol</i>. 1998;46(6):541-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9862242\">[PubMed 9862242]</a></p>\n<p>2. Namenda (memantine) [prescribing information]. St. Louis, MO: Forest Pharmaceuticals Inc; October 2013.</p>\n<p>3. Namzaric (memantine/donepezil) [prescribing information]. Clonshaug, Dublin, Ireland: Forest Pharmaceuticals Inc; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8966":"<p><b>Title</b> CycloSPORINE (Systemic) / Sevelamer</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is only a concern with oral administration of cyclosporine. Intravenous cyclosporine is not expected to interact with sevelamer.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sevelamer may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Consider monitoring cyclosporine serum concentrations more closely, monitoring for decreases in cyclosporine concentrations, if sevelamer is initiated in a cyclosporine treated patient. Monitor for increased cyclosporine concentrations if sevelamer is discontinued in a patient stabilized on concomitant therapy.</p> \n<p><b>Discussion</b> In one case report, a 70-year-old female liver transplant recipient on cyclosporine experienced a 50% decrease in cyclosporine trough concentrations that required a 42% increase in cyclosporine dose to maintain therapeutic serum concentrations.<sup>1</sup> Upon cyclosporine withdrawal, her cyclosporine levels rose 69%.<sup>1</sup> <br><br>In contrast, in a study of 10 adult and 8 pediatric renal transplant recipients receiving cyclosporine and mycophenolate mofetil, 4 days of sevelamer therapy (1.6 grams three times daily for adults, 1.2 grams three times daily for pediatric subjects) resulted in no change in the AUC, maximum serum concentration, or trough concentration of cyclosporine.<sup>2</sup><br><br>Prescribing information for sevelamer states that post-marketing reports have described decreases in cyclosporine concentrations requiring cyclosporine dose increases when used in combination with sevelamer. The possibility of a drug interaction between these agents cannot be excluded.<sup>3,4</sup><br><br>The mechanism of this potential interaction has not been investigated, but may be a result of sevelamer binding to cyclosporine or bile acids, inhibiting the absorption of cyclosporine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Guillen-Anaya MA, Jadoul M. Drug interaction between sevelamer and cyclosporin. <i>Nephrol Dial Transplant</i>. 2004;19(2):515. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14736993\">[PubMed 14736993]</a></p>\n<p>2. Pieper AK, Buhle F, Bauer S, et al. The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. <i>Nephrol Dial Transplant</i>. 2004;19(10):2630-2633. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15304561\">[PubMed 15304561]</a></p>\n<p>3. <i>Renvela</i> (sevelamer) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2014.</p>\n<p>4. <i>Renagel</i> (sevelamer) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8967":"<p><b>Title</b> Tacrolimus (Systemic) / Sevelamer</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is only a concern with oral administration of tacrolimus. Intravenous or sublingual administration of tacrolimus is not expected to interact with sevelamer.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sevelamer may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider monitoring tacrolimus serum concentrations more closely, monitoring for decreases in tacrolimus concentrations, if sevelamer is initiated in a tacrolimus treated patient. Monitor for increased tacrolimus concentrations if sevelamer is discontinued in a patient stabilized on concomitant therapy.</p> \n<p><b>Discussion</b> A case report describes a 55 year-old male kidney transplant recipient stabilized on tacrolimus therapy.<sup>1</sup> Upon initiation of sevelamer (800 mg three times daily), tacrolimus trough concentrations declined more than 50%.<sup>1</sup> Despite tacrolimus dose increases, serum levels did not reach the therapeutic range until sevelamer was discontinued. In this same patient, tacrolimus pharmacokinetics were determined after a single tacrolimus 1.5 mg dose during treatment with sevelamer and three days after sevelamer discontinuation. Tacrolimus 7-hour AUC and maximum serum concentration increased 141% and 32%, respectively, after sevelamer discontinuation compared with sevelamer treatment.<sup>1</sup><br><br>Prescribing information for sevelamer states that postmarketing reports have described decreases in tacrolimus concentrations requiring tacrolimus dose increases when used in combination with sevelamer. The possibility of a drug interaction between these agents cannot be excluded.<sup>2,3</sup><br><br>The mechanism of this potential interaction has not been investigated, but may be a result of sevelamer binding to tacrolimus, inhibiting its absorption.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Merkle M, Wornle M, Rupprecht HD. The effect of sevelamer on tacrolimus target levels. <i>Transplantation</i>. 2005;80(5):707. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16177649\">[PubMed 16177649]</a></p>\n<p>2. <i>Renvela</i> (sevelamer) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2014.</p>\n<p>3. <i>Renagel</i> (sevelamer) [prescribing information]. Cambridge, MA: Genzyme Corporation; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8980":"<p><b>Title</b> Olaparib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Olaparib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid use of strong CYP3A4 inhibitors in patients being treated with olaparib, if possible. If concurrent use cannot be avoided, the dose of olaparib should be reduced to 100 mg twice daily, and patients should be closely monitored for evidence of toxicity.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 57 patients with solid tumors, the strong CYP3A4 inhibitor itraconazole (200 mg daily for 7 days) increased the olaparib (100 mg single dose) AUC and maximum serum concentration 2.7-fold and 1.4-fold, respectively.<sup>1,2</sup><br><br>The olaparib prescribing information states that concurrent use of olaparib and strong CYP3A4 inhibitors should be avoided when possible, but if such a combination cannot be avoided, the olaparib dose should be reduced to 100 mg twice daily.<sup>2</sup><br><br>Olaparib is a substrate for CYP3A4, so the likely mechanism for this interaction is inhibition of the CYP3A4-mediated metabolism of olaparib.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dirix L, Swaisland H, Verheul HM, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. <i>Clin Ther</i>. 2016;38(10):2286-2299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27745744\">[PubMed 27745744]</a></p>\n<p>2. Lynparza (olaparib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8981":"<p><b>Title</b> Olaparib / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of moderate CYP3A4 inhibitors in patients being treated with olaparib, if possible. If concurrent use cannot be avoided, the dose of olaparib should be reduced to 150 mg twice daily, and patients should be closely monitored for evidence of toxicity.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 57 patients with solid tumors, the strong CYP3A4 inhibitor itraconazole (200 mg daily for 7 days) increased the olaparib (100 mg single dose) AUC and maximum serum concentration 2.7-fold and 1.4-fold, respectively.<sup>1,2</sup> Pharmacokinetic models predict that use of the moderate CYP3A4 inhibitor fluconazole would increase the olaparib AUC 2.2-fold.<sup>2</sup><br><br>The olaparib prescribing information states that concurrent use of olaparib and moderate CYP3A4 inhibitors should be avoided when possible, but if such a combination cannot be avoided, the olaparib dose should be reduced to 150 mg twice daily.<sup>2</sup><br><br>Olaparib is a substrate for CYP3A4, so the likely mechanism for this interaction is inhibition of the CYP3A4-mediated metabolism of olaparib.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dirix L, Swaisland H, Verheul HM, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. <i>Clin Ther</i>. 2016;38(10):2286-2299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27745744\">[PubMed 27745744]</a></p>\n<p>2. Lynparza (olaparib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8982":"<p><b>Title</b> Olaparib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Olaparib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid use of strong CYP3A4 inducers in patients being treated with olaparib.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 patients with solid tumors, the strong CYP3A4 inducer rifampin (600 mg daily for 14 days) decreased the olaparib (300 mg single dose) AUC and maximum serum concentration 87% and 71%, respectively.<sup>1,2</sup><br><br>Olaparib prescribing information states that concomitant use of olaparib and strong CYP3A4 inducers should be avoided.<sup>2</sup><br><br>Olaparib is a substrate for CYP3A4, so the likely mechanism for this interaction is induction of the CYP3A4-mediated metabolism of olaparib.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dirix L, Swaisland H, Verheul HM, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. <i>Clin Ther</i>. 2016;38(10):2286-2299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27745744\">[PubMed 27745744]</a></p>\n<p>2. Lynparza (olaparib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8983":"<p><b>Title</b> Olaparib / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of moderate CYP3A4 inducers in patients being treated with olaparib whenever possible. If such concurrent use cannot be avoided, olaparib effectiveness may be decreased.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 22 patients with solid tumors, the strong CYP3A4 inducer rifampin (600 mg daily for 14 days) decreased the olaparib (300 mg single dose) AUC and maximum serum concentration 87% and 71%, respectively.<sup>1,2</sup> A moderate CYP3A inducer, efavirenz, is predicted to decrease the AUC of olaparib by approximately 60%.<sup>2</sup><br><br>Olaparib prescribing information states that concomitant use of olaparib and moderate CYP3A4 inducers should be avoided.<sup>2</sup> If concurrent use cannot be avoided, olaparib effectiveness may be decreased.<sup>2</sup><br><br>Olaparib is a substrate for CYP3A4, so the likely mechanism for this interaction is induction of the CYP3A4-mediated metabolism of olaparib.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dirix L, Swaisland H, Verheul HM, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. <i>Clin Ther</i>. 2016;38(10):2286-2299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27745744\">[PubMed 27745744]</a></p>\n<p>2. Lynparza (olaparib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8984":"<p><b>Title</b> Insulins / Liraglutide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The recommendations for management of this interaction depend on whether liraglutide is used for the treatment of diabetes or for weight loss.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Liraglutide may enhance the hypoglycemic effect of Insulins. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If liraglutide is used for the treatment of diabetes (Victoza), consider insulin dose reductions when initiating liraglutide. The combination of liraglutide and insulin should be avoided if liraglutide is used exclusively for weight loss (Saxenda).</p>\n<div>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> Prescribing information for liraglutide warns that the risk of hypoglycemia is increased if liraglutide is used in combination with insulin.<sup>1,2</sup> If liraglutide is used for the treatment of diabetes (Victoza), insulin dose reductions should be considered to reduce the risk of hypoglycemia.<sup>1</sup> The manufacturer recommends avoiding the combination of liraglutide and insulin if liraglutide is used exclusively for weight loss (Saxenda).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Victoza</i> (liraglutide) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; January 2010.</p>\n<p>2. <i>Saxenda</i> (liraglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8985":"<p><b>Title</b> Anticoagulants / Edoxaban</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Edoxaban may enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid long-term coadministration of edoxaban with other anticoagulants. Some limited combined use may be indicated during periods of transition from one anticoagulant to another.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin<br><b>Exceptions</b> Acenocoumarol, Warfarin</p>\n</div> \n<p><b>Discussion</b> The use of edoxaban in combination with other anticoagulants is expected to increase the risk of bleeding and should be avoided outside of specific periods of transition from one agent to another.<sup>1</sup> Refer to the full Lexi-Drugs drug monograph for specific recommendations on switching anticoagulant treatment to or from edoxaban.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Savaysa</i> (edoxaban) [prescribing information]. Parsippany, NJ: Daiichi Sankyo Inc; January 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8986":"<p><b>Title</b> Edoxaban / P-glycoprotein/ABCB1 Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Recommendations for edoxaban dose adjustment apply to patients receiving the drug for venous thromboembolism but not for nonvalvular atrial fibrillation.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> When used for venous thromboembolism, limit the maximum adult edoxaban dose to 30 mg daily in patients receiving verapamil, quinidine, or short-term azithromycin, clarithromycin, erythromycin, oral itraconazole, or oral ketoconazole. Specific recommendations for use with other P-glycoprotein inhibitors are not available. No dose adjustment is recommended when P-glycoprotein inhibitors are used with edoxaban for treatment of nonvalvular atrial fibrillation.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> Edoxaban exposure increased during coadministration with several P-glycoprotein (P-gp) inhibitors in clinical studies of healthy volunteers: AUC, maximum concentration (Cmax), and 24-hour concentration (C24) increased by 85%, 43%, and 158%, respectively, with dronedarone; AUC, Cmax, and C24 increased by 77%, 75%, and 12%, respectively, with quinidine; AUC and C24 increased by 53%, and 29%, respectively, with sustained-release verapamil; and AUC and Cmax increased by 40% and 60%, respectively, while C24 decreased by 26% with amiodarone.<sup>1,2</sup> In another study, the edoxaban AUC increased 87%, 86%, and 73%, respectively, when coadministered with the P-gp inhibitors ketoconazole, erythromycin, and cyclosporine.<sup>3</sup> The anticoagulant effects of edoxaban (eg, PT, aPTT, Factor Xa inhibitory activity) were enhanced with P-gp inhibitor coadministration.<sup>3</sup><br><br>The suspected primary mechanism of these interactions is inhibition of P-glycoprotein-mediated transport of edoxaban. Edoxaban US prescribing information recommends its use at a reduced dose in combination with many of the studied agents (verapamil, quinidine, erythromycin, ketoconazole) and some related compounds.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Savaysa</i> (edoxaban) [prescribing information]. Parsippany, NJ: Daiichi Sankyo Inc; January 2015.</p>\n<p>2. Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. <i>Am J Cardiovasc Drugs</i>. 2013. 13(5):331-342. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23784266\">[PubMed 23784266]</a></p>\n<p>3. Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine [published online August 16, 2016]. <i>Br J Clin Pharmacol</i>. doi: 10.1111/bcp.13092. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27530188\">[PubMed 27530188]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8988":"<p><b>Title</b> Edoxaban / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Edoxaban. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of edoxaban and rifampin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 32 healthy volunteers, rifampin (600 mg daily x 7 days) decreased the edoxaban (60 mg single dose) AUC and half-life 35% and 52%, respectively.<sup>1</sup> The AUC of the M4 and M6 active edoxaban metabolites increased 179% and 186%, respectively, and the PT and aPTT values measured 2 and 4 hours after edoxaban administration were similar with and without rifampin coadministration.<sup>1</sup> Measurements of PT and aPTT were not assessed beyond 4 hours, so the effect of rifampin on the anticoagulant activity of edoxaban over the entire 24-hour dosing interval is unknown.<sup>1</sup><br><br>Edoxaban prescribing information states that concomitant use of edoxaban and rifampin should be avoided.<sup>2</sup><br><br>The suspected primary mechanism of this interaction is rifampin induction of P-glycoprotein-mediated edoxaban efflux.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Mendell J, Chen S, He L, Desai M, Parasramupria DA. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. <i>Clin Drug Investig</i>. 2015;35(7):447-453. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26068927\">[PubMed 26068927]</a></p>\n<p>2. Savaysa (edoxaban) [prescribing information]. Parsippany, NJ: Daiichi Sankyo Inc; September 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8990":"<p><b>Title</b> Rosuvastatin / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Clarithromycin may increase the serum concentration of Rosuvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Patients taking a non-CYP3A4-metabolized statin, such as rosuvastatin (approximately 76% of patients), with clarithromycin had a modest but statistically significant increase in the risk of hospital admission with hyperkalemia or acute kidney injury, and all-cause mortality compared to patients taking azithromycin (not a substantial inhibitor of OATP1B1) in a population based, retrospective cohort study of 104,041 patients aged 66 years and older.<sup>1</sup> There was a similarly modest, but non-statistically-significant increase in risk for hospitalization for rhabdomyolysis with clarithromycin vs. azithromycin. The absolute risk increase was quite small (0.02% to 0.11%) for these outcomes, largely due to the small numbers of events in both groups, resulting in estimates that more than 900 to 5000 patients would have to be exposed to this combination to result in one of these outcomes.<br><br>Whether rosuvastatin concentrations are altered by clarithromycin are not known, but the AUC of the non-CYP3A4-metabolized statin pravastatin was an average of 110% higher with concurrent use of clarithromycin (500 mg twice/day x 9 days).<sup>2</sup> Conversely, the rosuvastatin AUC was 20% lower with concurrent use of erythromycin (500 mg four times/day for 7 days).<sup>3</sup><br><br>Rosuvastatin is generally considered to be subject to a lower risk of having a significant interaction with the CYP3A4-inhibiting macrolide antibiotics (erythromycin, clarithromycin, telithromycin) due to its limited hepatic metabolism.<sup>3</sup> The most likely mechanism for any rosuvastatin-macrolide interaction is inhibition of the SLCO1B1 uptake transporter leading to reduced hepatic uptake of rosuvastatin. The disposition of many statins appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1), and clarithromycin and other macrolides may inhibit SLCO1B1 activity.<sup>4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Li DQ, Kim R, Mcarthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. <i>CMAJ</i>. 2014; Dec 22 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25534598\">[PubMed 25534598]</a></p>\n<p>2. <i>Pravachol</i> (pravastatin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2012.</p>\n<p>3. <i>Crestor</i> (rosuvastatin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2014.</p>\n<p>4. Seithel A, Eberl S, Singer K, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. <i>Drug Metab Dispos</i>. 2007;35(5):779-786. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17296622\">[PubMed 17296622]</a></p>\n<p>5. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy--a genomewide study. <i>N Engl J Med</i>. 2008;359(8):789-979. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>6. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. <i>Pharmacogenet Genomics</i>. 2006;16(12):873-879. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p>7. Igel M, Arnold KA, Niemi M, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. <i>Clin Pharmacol Ther</i>. 2006;79(5):419-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16678544\">[PubMed 16678544]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8991":"<p><b>Title</b> Fluvastatin / Clarithromycin</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Clarithromycin may enhance the adverse/toxic effect of Fluvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Patients taking a non-CYP3A4-metabolized statin (fluvastatin in only 2.3% of patients; more than 97% were taking rosuvastatin or pravastatin), with clarithromycin had a modest but statistically significant increase in the risk of hospital admission with hyperkalemia or acute kidney injury, and all-cause mortality compared to patients taking azithromycin (not a substantial inhibitor of OATP1B1) in a population based, retrospective cohort study of 104,041 patients aged 66 years and older.<sup>1</sup> There was a similarly modest, but non-statistically-significant increase in risk for hospitalization for rhabdomyolysis with clarithromycin vs. azithromycin. The absolute risk increase was quite small (0.02% to 0.11%) for these outcomes, largely due to the small numbers of events in both groups, resulting in estimates that more than 900 to 5000 patients would have to be exposed to this combination to result in one of these outcomes. Additionally, with so few patients using fluvastatin in this study, the degree to which these findings represent an interaction involving fluvastatin is unclear.<br><br>Fluvastatin is generally considered to have a lower risk of significant interaction with the CYP3A4-inhibiting macrolide antibiotics (erythromycin, clarithromycin, telithromycin) due to its primary dependence on CYP2C9, instead of CYP3A4, for its metabolism.<sup>2</sup> The proposed mechanism by which the other non-CYP3A4-dependent statins interact with clarithromycin is via inhibition of the SLCO1B1 uptake transporter by clarithromycin, leading to reduced hepatic uptake of the statin. The disposition of many statins appears to be at least somewhat dependent on the uptake transporter SLCO1B1 (OATP1B1),<sup>3,4,5,6</sup> but some evidence suggests fluvastatin may be somewhat unique in that it is not significantly transported by SLCO1B1.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Li DQ, Kim R, Mcarthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. <i>CMAJ</i>. 2014; Dec 22 (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25534598\">[PubMed 25534598]</a></p>\n<p>2. <i>Lescol XL</i> (fluvastatin) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2012.</p>\n<p>3. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy--a genomewide study. <i>N Engl J Med</i>. 2008;359(8):789-979. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18650507\">[PubMed 18650507]</a></p>\n<p>4. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. <i>Pharmacogenet Genomics</i>. 2006;16(12):873-879. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17108811\">[PubMed 17108811]</a></p>\n<p>5. Igel M, Arnold KA, Niemi M, et al. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. <i>Clin Pharmacol Ther</i>. 2006;79(5):419-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16678544\">[PubMed 16678544]</a></p>\n<p>6. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. <i>Clin Pharmacol Ther</i>. 2006;80(4):356-366. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17015053\">[PubMed 17015053]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8994":"<p><b>Title</b> Insulins / Pramlintide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pramlintide may enhance the hypoglycemic effect of Insulins. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control.</p>\n<div>\n <p><b>Insulins Interacting Members</b> Insulin (Oral Inhalation), Insulin Aspart, Insulin Degludec, Insulin Detemir, Insulin Glargine, Insulin Glulisine, Insulin Lispro, Insulin NPH, Insulin Regular</p>\n</div> \n<p><b>Discussion</b> Although pramlintide is unlikely to cause hypoglycemia alone, pramlintide US prescribing information warns that hypoglycemia (sometimes severe) has occurred when this agent is used in combination with insulin.<sup>1</sup> When initiating pramlintide, it is recommended to decrease mealtime insulin doses by 50% and frequently monitor blood glucose.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Symlin</i> (pramlintide) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8995":"<p><b>Title</b> Buprenorphine / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Buprenorphine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for evidence of excessive buprenorphine responses or toxicity when using buprenorphine together with a cobicistat-containing product.</p> \n<p><b>Discussion</b> The AUC of both buprenorphine and norbuprenorphine were significantly increased (by 35% and 42%, respectively), compared to baseline after coadministration with elvitegravir/cobicistat in a multiple dose, open-label, nonrandomized study of buprenorphine/naloxone in HIV-negative subjects taking elvitegravir/cobicistat with buprenorphine/naloxone (n=17).<sup>1,2</sup><br><br>Buprenorphine and norbuprenorphine are primarily metabolized by CYP3A4 and glucuronidation via UGT1A1 and UGT1A3. Cobicistat is a potent inhibitor of CYP3A, and thus is expected to inhibit the metabolism of buprenorphine and norbuprenorphine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bruce RD, Winkle P, Custodio JM, et al. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. <i>J Acquir Immune Defic Syndr</i>. 2013;63(4):480-484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23599011\">[PubMed 23599011]</a></p>\n<p>2. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8996":"<p><b>Title</b> Naloxone / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cobicistat may decrease the serum concentration of Naloxone. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The naloxone AUC was significantly decreased by 28% compared to baseline in a multiple dose, open-label, nonrandomized study of buprenorphine/naloxone in HIV-negative subjects taking elvitegravir /cobicistat (n=17) with buprenorphine/naloxone.<sup>1</sup> The clinical significance of this change not certain.<br><br>The mechanism leading to the AUC reduction of naloxone is unclear, as is any possible contribution from elvitegravir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bruce RD, Winkle P, Custodio JM, et al. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. <i>J Acquir Immune Defic Syndr</i>. 2013;63(4):480-484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23599011\">[PubMed 23599011]</a></p>\n<p>2. <i>Stribild</i> (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; December 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8997":"<p><b>Title</b> Levothyroxine / Magnesium Salts</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Only oral preparations of magnesium salts are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Magnesium Salts may decrease the serum concentration of Levothyroxine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n</div> \n<p><b>Discussion</b> Prescribing information for levothyroxine lists aluminum- and magnesium-containing antacids as agents that may prevent absorption of T4 from the gastrointestinal tract, and recommends that such agents be administered at least 4 hours apart from levothyroxine.<sup>1</sup> At least one report describes a patient receiving stable levothyroxine therapy whose serum thyrotropin concentrations became elevated during treatment with a magnesium-containing antacid, and returned to normal values following cessation of the antacid.<sup>2</sup> An in vitro study found that combinations of magnesium hydroxide, magnesium carbonate, and aluminum hydroxide were capable of adsorbing levothyroxine in a dose-dependent manner, but that magnesium oxide alone did not significantly adsorb levothyroxine.<sup>2</sup><br><br>The likely primary mechanism of this interaction is adsorption of levothyroxine to magnesium and/or aluminum in the gastrointestinal tract.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Synthroid</i> (levothyroxine sodium) [prescribing information]. North Chicago, IL: Abbott Laboratories; May 2009.</p>\n<p>2. Mersebach H, Rasmussen AK, Kirkegaard L, Feldt-Rasmussen U. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. <i>Pharmacol Toxicol</i>. 1999;84(3):107-109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10193669\">[PubMed 10193669]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8998":"<p><b>Title</b> Glucagon / Anticholinergic Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Concomitant use of glucagon and anticholinergic agents is not recommended when glucagon is used as a diagnostic aid. When glucagon is used as an emergency treatment for hypoglycemia, monitor for increased gastrointestinal adverse effects.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased gastrointestinal adverse effects when glucagon is combined with with anticholinergic agents. Seek alternatives to this combination when using glucagon as a diagnostic aid in order to avoid the increased risk of gastrointestinal adverse effects.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The glucagon prescribing information states that the concomitant use of anticholinergic drugs and glucagon may increase the risk of gastrointestinal adverse reactions due to<br>additive effects on inhibition of gastrointestinal motility.<sup>1</sup> Use of glucagon in combination with anticholinergic agents is not recommended due to an expected increase in the risk of gastrointestinal adverse effects.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. GlucaGen (glucagon) [prescribing information]. Princeton, NJ: Novo Nordisk Inc; December 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8999":"<p><b>Title</b> Fibric Acid Derivatives / Ciprofibrate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ciprofibrate may enhance the adverse/toxic effect of Fibric Acid Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of ciprofibrate with any other fibric acid derivative due to the increased risk of muscle toxicities, including rhabdomyolysis. This combination is specifically contraindicated in product labeling for ciprofibrate.</p>\n<div>\n <p><b>Fibric Acid Derivatives Interacting Members</b> Bezafibrate, Ciprofibrate, Fenofibrate and Derivatives, Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> Since fibric acid derivatives have been found to increase the risk of muscle toxicities,<sup>1,2,3</sup> the combined use of more than one fibric acid derivative is likely to increase this risk. For this reason, ciprofibrate product labeling specifically contraindicates the use of ciprofibrate with another fibric acid derivative.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. <i>PLoS One</i>. 2008;3(6):e2522. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18575628\">[PubMed 18575628]</a></p>\n<p>2. Ciprofibrate [summary of product characteristics]. Harlington Road, Hillingdon, UK: NRIM Limited; November 2014.</p>\n<p>3. Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. <i>Eur J Clin Pharmacol</i>. 2009;65(12):1169-1174. PubMed 19756555]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}